Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients

Internal Medicine

Volumn 47, Issue 21, 2008, Pages 1851-1857

  Fogari, Roberto ^a   Preti, Paola ^a   Zoppi, Annalisa ^a   Mugellini, Amedeo ^a   Corradi, Luca ^a   Lazzari, Pierangelo ^a   Santoro, Tara ^a   Derosa, Giuseppe ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Amlodipine; Hypertension; Insulin sensitivity; Obesity; Overweight; Valsartan

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS VALSARTAN; GLUCOSE; INSULIN; PLACEBO; VALSARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMAN; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AMLODIPINE; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; INSULIN; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PROSPECTIVE STUDIES; TETRAZOLES; VALINE;

EID: 56349127740     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.1427     Document Type: Article

References (53)

1. Brown CD, Higgins M, Donato KA. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 8: 605-619, 2000.
2. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH; American Heart Association, Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 113 (6): 898-918, 2006.
3. Sowers JR. Obesity as a cardiovascular risk factor. Am J Med 115 (8A): 37S-41S, 2003.
4. Antonini L, Grosso A, Francalanci C, Mattei R. Cardiovascular pathophysiology of obesity. High Blood Press Cardiovasc Prev 14: 207-212, 2007.
5. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 106: 473-481, 2000.
6. Imazu M. Hypertension and insulin disorders. Curr Hypertens Rep 6: 477-482, 2002.
7. Dentali F, Sharma AM, Douketis JD. Management of hypertension in overweight and obese patients: a practical guide for clinicians. Curr Hypertens Rep 7: 330-336, 2005.
8. Wenzel UO, Krebs C. Treatment of arterial hypertension in obese patients. Contrib Nephrol 151: 230-242, 2006.
9. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Roccella EJ, Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 36: 594-599, 2000.
10. Bramlage P, Pittrow D, Wittchen HU, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 17: 904-910, 2004.
11. Pollare T, Lithell H, Berne CA. Comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321: 868-873, 1989.
12. Reaven GM, Clinkingbeard C, Jeppesen J, et al. Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens 8: 461-466, 1995.
13. Trost BN, Weidman P. Effects of calcium antagonists on glucose homeostasis and serum lipids in non-diabetic and diabetic subjects: a review. J Hypertens 5: S81-S104, 1987.
14. Beer NA, Jakubowicz DJ, Beer RM, Arocha IR, Nestler JE. Effects of nitrendipine on glucose tolerance and serum insulin and dehydroepiandrosterone sulfate levels in insulin-resistant obese and hypertensive men. J Clin Endocrinol Metab 76: 178-183, 1993.
15. Ueshiba H, Miyachi Y. Effects of long acting calcium-channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. Intern Med 43: 561-565, 2004.
16. Torlone E, Britta A, Rambotti AM. Improved insulin action and glycemic control after long term angiotensin converting anzyme inhibition in subjects with arterial hypertension and type II diabetes. Diabetes Care 16: 1347-1355, 1993.
17. Grassi G, Seravalle G, Dell'Oro R, et al; CROSS Study. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity and sympathetic drive in obese hypertensives individuals: results of the Cross study. J Hypertens 21: 1761-1769, 2003.
18. Abuissa H, Jones PG, Marso SP, O'Keefe JH. Angiotensin converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 46: 821-826, 2005.
19. Egan BM. Combination therapy with an angiotensin-converting enzyme inhibitor and a calcium channel blocker. J Clin Hypertens 9: 783-789, 2007.
20. Hansson L, Hedner T, Dahlof B. Prospective, Randomized, Open, Blinded End-point (PROBE) study: a novel design for intervention trials. Blood Press 1: 113-114, 1992.
21. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237: E214-E223, 1979.
22. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 29: 563-580, 2007.
23. Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 29: 279-289, 2007.
24. Bakris GL. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens 10 (Suppl 1): 27-32, 2008.
25. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 17: 305-322, 2003.
26. Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens 22: 1453-1458, 2004.
27. Baron AD, Brechtel GB, Waqllace P, Edelman SV. Rates and tissue sites of non-insulin and insulin-mediated glucose uptake in humans. Am J Physiol 255: E769-E774, 1988.
28. Draznin B, Sussman KE, Eckel RH, Kao M, Yost T, Sherman MA. Possible role of cytosolic free calcium in mediating insulin resistance in obesity and hyperinsulinemia. J Clin Invest 82: 1848-1852, 1988.
29. Laakso M, Karjalaainen L, Lempiainen-Kuosa P. Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertension 28: 392-396, 1996.
30. Moan A, Hoieggen A, Seljeflot I, Risanger T, Arnesen H, Kjeldsen SE. The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 14: 1083-1097, 1996.
31. Fogari R, Zoppi A, Corradi L, Lazzari P, Mugellini A, Lusardi P. Comparative effect of lisinopril and losartan on insulin sensitività in the treatment of non diabetic hypertensive patients. Br J Clin Pharmacol 46: 467-471, 1998.
32. Furuhashi M, Ura N, Takizawa H, et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 22: 1977-1982, 2004.
33. Aksnes TA, Reims HM, Guptha S, Moan A, Os I, Kjeldsen SE. Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors. J Hum Hypertens 20: 860-866, 2006.
34. Julius S, Kjeldsen SE, Weber M, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 363: 2022-2031, 2004.
35. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 41: 127-133, 1998.
36. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 23: 463-473, 2005.
37. Munoz MC, Argentino DP, Dominici FP, Turyn D, Toblli JE. Irbesartan restores the in-vivo insulin signaling pathway leading to Akt activation in obese Zucker rats. J Hypertens 24: 1607-1617, 2006.
38. Henriksen EJ, Jacobs S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38: 884-890, 2001.
39. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109: 2054-2057, 2004.
40. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86: 1930-1935, 2001.
41. Koh KK, Quon MJ, Han SH, Chung WJ, Lee Y, Shin EK. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 108: 96-100, 2006.
42. Yilmaz MI, Sonmez A, Caglar K, et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton) 12: 147-153, 2007.
43. Yamaguchi K, Ura N, Murakami H, et al. Olmesartan ameliorates insulin sensitivity by modulating tumor necrosis factor-α and cyclic AMP in skeletal muscle. Hypertens Res 28: 773-778, 2005.
44. Kurata A, Nishizawa H, Kihara S, et al. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 70: 1717-1724, 2006.
45. Sharma AM, Janke J, Gozelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type II diabetes by formation of fat cells. Hypertension 40: 609-611, 2002.
46. Sandhu MS, Head AH, Gibson JM. Circulating concentrations of insulin-like growth factor-I and development of glucose tolerance: a prospective observational study. Lancet 359: 1740-1745, 2002.
47. Zandbergen AA, Lamberts SW, Janssen JA, Bootsma AH. Shortterm administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-1. Eur J Endocrinol 155: 293-296, 2006.
48. Zandbergen AA, Lamberts SW, Baggen MG, Janssen JA, Boersma E, Bootsma AH. The IGF-I system and the renal and hemodynamic effects of losartan in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial. Clin Endocrinol 64: 203-208, 2006.
49. Rahmouni K, Haynes WG. Leptin and the cardiovascular system. Recent Prog Horm Res 59: 225-244, 2004.
50. Umeda M, Kanda T, Murakami M. Effects of angiotensin II receptor antagonists on insulin resistance syndrome and leptin in sucrose-fed spontaneously hypertensive rats. Hypertens Res 26: 485-492, 2003.
51. Fogari R, Derosa G, Zoppi A, et al. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res 28: 209-214, 2005.
52. Barton M, Carmona R, Ortmann J, Krieger JE, Traupe T. Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. Int J Biochem Cell Biol 35: 826-837, 2003.
53. Ferrannini E, Seghieri G, Muscelli E. Insulin and the renin-angiotensin-aldosterone system: influence of ACE inhibition. J Cardiovasc Pharmacol 24 (Suppl 3): S61-S69, 1994.